Hallucinogen use, unspecified with hallucinogen-induced mood disorder
ICD-10 F16.94 is a billable code used to indicate a diagnosis of hallucinogen use, unspecified with hallucinogen-induced mood disorder.
F16.94 refers to a condition characterized by the use of hallucinogenic substances that leads to a mood disorder. Hallucinogens, such as LSD, psilocybin, and mescaline, can significantly alter perception, mood, and cognitive processes. When an individual uses these substances, they may experience various psychological effects, including hallucinations, altered reality, and mood disturbances. The mood disorder associated with hallucinogen use can manifest as depression, anxiety, or mood swings, which may require clinical intervention. The unspecified nature of the code indicates that the specific hallucinogen used is not documented, making it essential for healthcare providers to thoroughly assess the patient's substance use history. Treatment often involves a combination of psychotherapy, support groups, and, in some cases, pharmacotherapy to manage mood symptoms. Understanding the complexities of hallucinogen use and its psychological impact is crucial for effective treatment and recovery.
Detailed patient history, including substance use and mood symptoms.
Patients presenting with mood swings or depressive symptoms following hallucinogen use.
Consideration of co-occurring mental health disorders and substance use history.
Comprehensive assessment of substance use patterns and treatment history.
Patients in withdrawal or experiencing cravings for hallucinogens.
Integration of behavioral therapies and pharmacological interventions.
Used when assessing the impact of hallucinogen use on mood.
Document the assessment findings and treatment plan.
Psychiatrists may use this code for comprehensive evaluations.
F16.94 is significant as it captures the relationship between hallucinogen use and mood disorders, allowing for appropriate treatment and management of affected individuals.
